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ARTICLE
Age-Related Somatic Structural Changes
in the Nuclear Genome of Human Blood Cells
Lars A. Forsberg,1 Chiara Rasi,1 Hamid R. Razzaghian,1 Geeta Pakalapati,1 Lindsay Waite,2
Krista Stanton Thilbeault,2 Anna Ronowicz,3 Nathan E. Wineinger,4 Hemant K. Tiwari,4
Dorret Boomsma,5 Maxwell P. Westerman,6 Jennifer R. Harris,7 Robert Lyle,8 Magnus Essand,1
Fredrik Eriksson,1 Themistocles L. Assimes,9 Carlos Iribarren,10 Eric Strachan,11 Terrance P. O’Hanlon,12
Lisa G. Rider,12 Frederick W. Miller,12 Vilmantas Giedraitis,13 Lars Lannfelt,13 Martin Ingelsson,13
Arkadiusz Piotrowski,3 Nancy L. Pedersen,14 Devin Absher,2 and Jan P. Dumanski1,*
Structural variations are among the most frequent interindividual genetic differences in the human genome. The frequency and distri-
bution of de novo somatic structural variants in normal cells is, however, poorly explored. Using age-stratified cohorts of 318 monozy-
gotic (MZ) twins and 296 single-born subjects, we describe age-related accumulation of copy-number variation in the nuclear genomes
in vivo and frequency changes for both megabase- and kilobase-range variants. Megabase-range aberrations were found in 3.4% (9 of
264) of subjects R60 years old; these subjects included 78 MZ twin pairs and 108 single-born individuals. No such findings were
observed in 81MZ pairs or 180 single-born subjects whowere%55 years old. Recurrent region- and gene-specificmutations, mostly dele-
tions, were observed. Longitudinal analyses of 43 subjects whose data were collected 7–19 years apart suggest considerable variation in
the rate of accumulation of clones carrying structural changes. Furthermore, the longitudinal analysis of individuals with structural aber-
rations suggests that there is a natural self-removal of aberrant cell clones from peripheral blood. In three healthy subjects, we detected
somatic aberrations characteristic of patients with myelodysplastic syndrome. The recurrent rearrangements uncovered here are candi-
dates for common age-related defects in human blood cells. We anticipate that extension of these results will allow determination of the
genetic age of different somatic-cell lineages and estimation of possible individual differences between genetic and chronological age.
Our work might also help to explain the cause of an age-related reduction in the number of cell clones in the blood; such a reduction is
one of the hallmarks of immunosenescence.
Introduction
Structural changes in the human genome have been iden-
tified as one of the major types of interindividual genetic
variation.1,2 Furthermore, the rate of formation of copy-
number variants (CNVs) exceeds the corresponding rate
of SNPs by 2–4 orders of magnitude.3–5 In spite of this, little
is known about the rate of formation and distribution of
de novo somatic CNVs in normal cells and whether these
aberrations accumulate with age. There are, however, indi-
cations that chromosomal remodeling in the nuclear and
mitochondrial genomes increases with age.6–12 Theoretical
predictions suggest that somatic mosaicism should be
widespread,13,14 and reviews in the field point out that
somatic mosaicism, in both healthy and diseased cells, is
an understudied aspect of human-genome biology.15–18
A recent estimate of 1.7% for the frequency with which
somatic mosaicism causes large-scale structural aberrations
in adult human samples is, however, a relatively low
number.19 We have shown that adult monozygotic (MZ)
twins and differentiated human tissues frequently display
somatic CNVs.20,21 We therefore hypothesized that the
nuclear genome of blood cells in vivo might accumulate
CNVs with age, and we used age-stratified MZ twins as
a starting point for testing this hypothesis. Because nuclear
genomes of MZ twins are identical at conception, they
represent a good model for studying somatic variation.
We replicated a MZ-twin-based analysis by using age-strat-
ified cohorts of single-born subjects. Using these resources,
we show age-related accumulation of CNVs in the nuclear
genomes of blood cells in vivo. Age effects were found for
both megabase- and kilobase-range variants.
1Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden; 2HudsonAlpha Institute for
Biotechnology, 601 Genome Way, Huntsville, AL 35806, USA; 3Department of Biology and Pharmaceutical Botany, Medical University of Gdansk, Hallera
107, 80-416 Gdansk, Poland; 4Section on Statistical Genetics, Department of Biostatistics, Ryals Public Health Building, University of Alabama at Birming-
ham, Suite 327, Birmingham, AL 35294-0022, USA; 5Department of Biological Psychology, VU University, Van der Boechorststraat 1, 1081 BT Amsterdam,
The Netherlands; 6Hematology Research, Mount Sinai Hospital Medical Center, 1500 S California Avenue, Chicago, IL 60608, USA; 7Department of Genes
and Environment, Division of Epidemiology, The Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, N-0403 Oslo, Norway; 8Department of
Medical Genetics, Oslo University Hospital, Kirkeveien 166, 0407 Oslo, Norway; 9Department of Medicine, Stanford University School of Medicine,
Stanford, CA 94305, USA; 10Kaiser Foundation Research Institute, Oakland, CA 94612, USA; 11Deptartment of Psychiatry and Behavioral Sciences and
University of Washington Twin Registry, University of Washington, Box 359780 Seattle, WA 98104, USA; 12Environmental Autoimmunity Group,
National Institute of Environmental Health Sciences, National Institutes of Health Clinical Research Center, National Institutes of Health, Building 10,
Room 4-2352, 10 Center Drive, MSC 1301, Bethesda, MD 20892-1301, USA; 13Department of Public Health and Caring Sciences, Division of Molecular
Geriatrics, Rudbeck laboratory, Uppsala University, 751 85 Uppsala, Sweden; 14Department ofMedical Epidemiology and Biostatistics, Karolinska Institutet,
SE-171 77 Stockholm, Sweden
*Correspondence: jan.dumanski@igp.uu.se
DOI 10.1016/j.ajhg.2011.12.009. 2012 by The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics 90, 217–228, February 10, 2012 217
Material and Methods
Studied Cohorts, DNA Isolation, and Quality Control
Samples were collected with informed consent from all subjects,
and the study was approved by the respective local institutional
review boards or research ethics committees. The information
about studied cohorts of MZ twins and single-born subjects is
provided in Tables S1 and S2, available online. We isolated DNA
from peripheral blood by using the QIAGEN kit (QIAGEN, Hilden,
Germany).
The quality, quantity, and integrity of DNA samples were
controlled with NanoDrop (Thermo Fisher Scientific, Waltham,
MA, USA), picoGreen fluorescent assay (Invitrogen, Eugene, Ore-
gon, USA), and agarose gels.
Sorting of Subpopulations of Cells from Peripheral
Blood and Culturing of Fibroblasts
Peripheral blood mononuclear cells (PBMCs) were isolated from
the whole blood with Ficoll-Paque centrifugation (Amersham
Biosciences, Uppsala, Sweden), and a mixture of granulocytes
was collected from under the PBMC layer. We isolated CD19þ cells
from PBMCs by positive selection with CD19 MicroBeads (Milte-
nyi Biotech, Auburn, CA, USA). First, we negatively selected
CD4þ cells by using the CD4þ T cell Isolation Kit II (Miltenyi
Biotech, Auburn, CA, USA), and then we positively selected the
cells by using CD4 MicroBeads (Miltenyi Biotech, Auburn, CA,
USA). The CD19þ and CD4þ cells were incubated for 30 min at
4C with phycoerythrin- and PerCP-conjugated antibodies (BD
Biosciences, San Diego, CA, USA), respectively, for fluorescence-
activated cell sorting (FACS) analysis. We measured purities
of >90% for CD19þ and >98% for CD4þ cells by flow cytometry
(FACS CantoII, BD Biosciences, San Diego, CA,USA). The skin-
biopsy-derived fibroblasts were cultured in RPMI medium
supplemented with Hams F-10 medium, fetal bovine serum
(10%), penicillin, and L-glutamine (all cell culture reagents were
from GIBCO, Invitrogen, Paisley, UK) in an incubator at 37C.
After reaching ~90% confluence, the cells were trypsinized
(Trypsin-EDTA, GIBCO, Invitrogen, Paisley, UK), and the fibro-
blasts were used for DNA isolation. We performed a standard
phenol-chloroform extraction to isolate DNA from CD19þ cells,
CD4þ cells, fibroblasts, and crude granulocyte fraction.
Genotyping with Illumina SNP Arrays and Calling
of Large-Scale CNVs
We performed the SNP genotyping experiments by using several
types of Illumina beadchips according to the recommendations of
the manufacturer. Such experiments were performed at two facili-
ties: Hudson Alpha Institute for Biotechnology (Huntsville, AL,
USA) and the SNP Technology Platform (Uppsala University,
Sweden). All Illumina genotyping experiments passed the follow-
ing quality-control criteria: The SNP call rate for all samples was
>98%, and the LogRdev value was <0.2. The results from Illumina
SNP arrays consist of two main data tracks: log R ratio (LRR) and
B-allele frequency (BAF)22 (see Figure 1). Deviations of consecutive
probes from normal states are indicative of structural aberrations.
We analyzed Illumina output files by using Nexus Copy Number
version 5.1 (BioDiscovery, CA, USA), which applies a ‘‘Rank
Segmentation’’ algorithm based on the circular binary segmenta-
tion (CBS) approach.23 The applied version, ‘‘SNPRank Segmenta-
tion,’’ an extended algorithm inwhich BAF values are also included
in the segmentation process, generated both copy-number and
allelic-event calls. We applied the default calling parameters of
the program. The array data for large-scale CNVs reported in this
paper have been submitted to the Database of Genomic Structural
Variation (dbVAR) under the accession number nstd58.
A Method for Detection of Small-Scale CNVs
with Illumina SNP Array Data
We developed and applied an algorithm for testing whether
smaller structural variants would also accumulate with age. We
used deviations in BAF as the main tool for detecting candidate
CNV regions because it can detect mosaicism in as low as 5%–
7% of cells24,25 and allows uncovering of deletions and duplica-
tions as well as copy-number-neutral loss of heterozygozity
(CNNLOH). This method uses an in-house-developed R-script26
to perform scans for deviations in BAF values alone and in BAF
values together with LRR values in MZ twins. Figure S1 describes
this algorithm, which identifies CNV calls for each MZ pair at
user-defined thresholds of either DBAF or both DBAF and DLRR.
Our initial tests of the algorithm were based on the entire cohort
of 159 MZ pairs. However, a series of ‘‘trial and error’’ tests sug-
gested that the method is sensitive to the quality of input data,
given that the results were heavily biased toward detection of
putative CNV calls in MZ co-twins with lower quality of genotyp-
ing, as measured by the Nexus Quality (NQ) score. The latter is one
of the features of Nexus Copy Number software. We therefore
defined strict NQ-score-based criteria for inclusion of MZ pairs in
the analysis (see Table S3 and Figure S1), which resulted in the
selection of 87 pairs that were processed further.
We based the final analysis on 87 twin pairs by identifying
candidate CNV loci in which BAF values were different between
co-twins when multiple thresholds were used. As expected, the
number of putative CNV calls between MZ co-twins was highly
dependent on the settings of the DBAF filtering (Figures S1–S4).
Thus, when the settings were too generous in this step, an age-
related signal was hidden in large background variation (Figure S2).
By using more strict filtering criteria, we found an age-related
correlation (Figures 2A and S4C). We trimmed the list of putative
CNVs generated by DBAF by using a DLRR filter of >0.35 so that
only loci with differences in both BAF and LRR remained in the
final list (Figures 2B and S4D). Hence, the DLRR filter removed
all loci with copy-number-neutral variation from the list. In the
course of tuning DBAF (or both DBAF and DLRR) filtering parame-
ters, we took advantage of three already-known large-scale aberra-
tions that are described in our dataset (Figures 1A–1F, 3, and S5).
These worked as ideal internal controls for the validity of our
approach as shown in Figures S2–S4. Hence, by plotting the
number of calls both including the probes locatedwithin the three
known aberrations (Figures S2A–S2B, S3A–S3B, and S4A–S4B) and
after excluding the probes located within the known aberrations
(Figures S2C–S2D, S3C–S3D, and S4C–S4D), we could compare
and evaluate the observed and expected results. For example, in
Figure S4B, the twin pair TP25-1/TP25-2 sticks out because the
probes positioned within the large de novo aberration of chromo-
some 5 (Figure 1) are included in the list of calls. When plotting
the same data after excluding probes within this region, we found
that the twin pair falls into the cluster of variation similar to that
of the other MZ twin pairs (Figure S4D). On the basis of such eval-
uations, we observed that probes within the three large-scale
CNVs were detected (or not, depending on the input file used in
the analysis) as predicted by our DBAF and DLRR algorithm. There-
fore, these evaluations provided an internal validation of our
approach to detecting de novo small-scale CNVs.
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Figure 1. Two Examples of Megabase-Range De Novo Somatic Aberrations
(A) A normal profile of MZ twin TP25-1.
(B) A 32.5 Mb deletion on 5q is shown in nucleated blood cells of co-twin TP25-2. This deletion was uncovered with LRR data from the
Illumina SNP array.
(C and D) The BAF profiles of twins TP25-1 (C) and TP25-2 (D). The qPCR experiments showed that 66.2% of nucleated blood cells in
TP25-2 had the 5q deletion (i.e., 33.1% fewer copies of the DNA segment, Figure 5). The R-package-MAD (Mosaic Alteration Detection)
analysis of the Illumina data suggested that 50.5% of the cells had the 5q deletion when the subjects were 77 years old.
(E) The deviation of BAF values from 0.5 (the allelic fraction of intensity at each heterozygous SNP) was plotted, and the percentage of
cells with the 5q deletion was higher when the subjects were 77 years old than when they were 70 years old (t test: p < 0.001). This slow
increase in aberrant clones was also supported by the MAD estimate of 48.3% of cells detected when the subjects were 70 years old. The
size and position of this deletion is typical of patients with myelodysplastic syndrome (MDS).
(F) A confirmatory array-CGH experiment.
(G–K) Another large somatic event: a terminal CNNLOH encompassing 103 Mb of 4q in ULSAM-697. The LRR and BAF data from
Illumina SNP genotyping of samples collected when the subjects were 71, 82, 88, and 90 years old are plotted in (G), (H), (I), and (J),
respectively. Percentages of cells with the aberration were calculated with the MAD package and are given for each panel.
(K) The proportion of cells with the 4q aberration changes with time, and the changes are significantly different between all samplings at
different ages (ANOVA: F(3,25935)¼ 39087, p< 0.001; Tukey’s test for multiple comparisons). Figure S8 shows other analysis details of the
samples collected fromULSAM-697 when he was 90 years old. These analyses include those of fibroblasts and three types of sorted blood
cells. The analysis of samples obtained when the subjects were 90 years old was performed in duplicate experiments on Illumina 1M-Duo
and Omni-Express arrays.
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Design of the Nimblegen 135K Custom-Made
Tiling-Path Oligonucleotide Array
This tool was designed according to the instructions from Roche-
Nimblegen (Madison, WI, USA) and encompassed 137,545 probes
used for validation of the 138 putative CNVs detected by the Illu-
mina SNP array (Figures 2B, S4C, and S4D). In total, the design
consisted of 98,894 experimental probes and an additional
38,651 backbone control probes distributed across the genome.
The median overlap of probes (i.e., probe spacing) was 30 bp.
This array was applied in cohybridizations of 34 MZ twin pairs
(Figures 2G, 2H, and S6 and Table S4).
Array-Comparative Genomic Hybridization
with Nimblegen 720K and 135K Arrays
We performed DNA labeling for both platforms (3 3 720K and
12 3 135K) by using the random priming with the Nimblegen
Dual-Color DNA Labeling kit (Roche-Nimblegen) according to
Nimblegen’s protocol. In brief, test and reference DNA (500 ng
each) samples were labeled with Cy3 and Cy5, respectively. The
combined test and reference DNA was cohybridized (for 48 hr at
42C) onto a human comparative genomic hybridization (CGH)
3 3 720K whole-genome tiling array (100718_HG18_WH_
CGH_v3.1_HX3, OID:30853; Roche-Nimblegen) or a 12 3 135K
custom-designed array (110131_HG18_LF_CGH_HX18, OID:
33469; Roche-Nimblegen). The arrays were washed with the
Nimblegen Wash Kit. We performed image acquisition with MS
200 Scanner at 2 mm resolution by using high-sensitivity and auto-
gain settings. We extracted data with NimbleScan v2.6 segMNT,
including spatial correction (LOESS) and qspline fit normalization,
in order to compensate for differences in signal between the two
dyes.27 We generated an experimental metrics report with
NimbleScan v2.6 to verify hybridization quality. We performed
CNV analysis with Nexus Copy Number software version 5.1 by
using default settings (see above). All plots shown in Figures 2G,
2H, and S6 are derived from unaveraged, normalized raw data.
Validation Experiments Involving Quantitative
Real-Time Polymerase Chain Reaction
We measured the relative amount of DNA molecules by using
quantitative real-time polymerase chain reaction (qPCR) with
SYBR green to validate the CNV findings from the arrays. qPCRs
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Figure 2. Age-Related Accumulation of Small Somatic Structural
Rearrangements in 87 Pairs of MZ Twins
(A and B) Linear regression analyses showing that the number of
calls increases with age in MZ twin pairs when DBAF values are
between 0.2 and 0.45 as well as when DBAF values are between
0.2 and 0.45 and when the LRR deviation is>0.35. Each dot repre-
sents data from one MZ twin pair. Details regarding the filtering
algorithms used are shown in Figure S1.
(C and D) An analysis of statistical significance for nine age groups
of MZ twin pairs when DBAF values are between 0.2 and 0.45.
(E and F) Longitudinal data analyses comparing the number of
DBAF reports (between 0.2 and 0.45) of 18 twin pairs that were
sampled twice, 10 years apart. Each point in the plot represents
the number of differences within one MZ pair (E). Each line
(plotted between the two time points for the same MZ pair) thus
represents the change over time of the number of differences
within a pair (blue line, increase; red line, decrease; green line,
no change). The intraindividual changes for each twin over
a period of 10 years are shown in (F). The x axis shows individual
ages at the later sampling. On the y axis, the number of differences
found between the two samples from the same person at the two
time points is shown, and vertical lines connect co-twins.
(G and H) Validation of copy-number imbalance between MZ
twins in two pairs (chromosomes 10 and 6, respectively), which
were detected by the DBAF analysis. The small boxes at the top
of both (G) and (H) display original data from Illumina arrays
for pairs TP63-1/TP63-2 and TP31-1/TP32-2, respectively. The
larger boxes at the bottom of (G) and (H) display raw data from
Nimblegen tiling-path 135K array for these two twin pairs. Each
line is drawn to scale and represents data from one oligonucleotide
probe. Statistical significance for the results of the Nimblegen
array was calculated with the Mann-Whitney U test; values were
analyzed for the region of interest (shaded) and for both areas
on either side of the control regions. Twenty additional examples
of validation experiments are shown in Figure S6. There was no
difference between the rates of validation success for the young
(n ¼ 8) and old (n ¼ 26) MZ pairs used in these experiments
(t test: t ¼ 0.7062, p value ¼ 0.4819), supporting the results
from linear-regression analyses. The detailed description of the
Nimblegen array is provided in Figure S6 and Table S4.
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were performed in 20 ml reactions containing 5 ng genomic DNA,
0.3 mM of each primer, and 13 Maxima SYBR Green/ROX qPCR
Master Mix (Fermentas, Vilnius, Lithuania) (for primer sequences,
see Table S5). The reactions were incubated at 95C for 10 min,
after which they underwent 40 cycles of 95C for 15 s and 60C
for 60 s in a Stratagene Mx3000P (Agilent Technologies) machine.
The reactions for evaluation of primer efficiencies were performed
in duplicates with control DNA (normal human female genomic
DNA, Promega Corporation, Madison,WI, USA), whereas all other
reactions with test and reference DNA were performed in tripli-
cates; in both instances, the averages were used in analyses. Each
primer pair’s efficiency and standard curve are described in
Figure S7. Melting-curve analysis was performed in all the experi-
Figure 3. An Example of a Somatic
Megabase-Range Aberration
(A, E, and F) A deletion encompassing
12.9 Mb of 20q in MZ twin TP30-1 was
sampled when she was 69 years old.
(B, G, and H) The normal profile of co-twin
TP30-2, as detected by LRR and BAF
after Illumina SNP array genotyping.
R-package-MAD analysis of the Illumina
data suggested that 41.5% of the blood
cells had the 20q deletion. qPCR valida-
tion experiments confirmed this result
by showing 39.6% aberrant cells (i.e.,
19.8% fewer copies of the DNA segment,
Figure 5).
(C and D) Array-CGH validation experi-
ments also confirmed the copy-number
variation. The genetic change in MZ twin
TP30-1 is another example of an MDS-like
aberration, which was uncovered in a
subjectwithout a clinical diagnosis ofMDS.
ments, and the results were analyzed with
MxPro v4.10 software. We used ultra-
conserved elements on human chromo-
somes 3 and 6 (UCE3 andUCE6) as control
loci as previously described.28,29 We used
the average cycle threshold (Ct) value of
UCE6 to normalize the average Ct values
of UCE3 and test loci. We used these
normalized Ct values to calculate copy-
number ratios of test regions. Using the
estimated copy-number ratios from UCE3
and the test loci from multiple replicate
experiments, we performed t tests for
statistical testing.
Statistical Methods
The statistical analyses were performed
with the R 2.12–2.13 software.26 We used
methods such as linear regression, t tests,
andone-wayanalyses of variance (ANOVAs)
when suitable, as further specified in the
text. Prior to testing, we controlled the data
so that no test assumptions were violated.
For multiple comparisons (i.e., Figures 1K
and S8G), we used the Tukey honest-signifi-
cant-difference method by implementing
the TukeyHSD function in R. When appro-
priate, we performed the nonparametric Fisher’s exact test and
Mann-Whitney U test, as described in the text.
Boxplots of Longitudinal-Analysis Data
Heterozygous SNPs have a theoretical expected BAF value of 0.5,
and deviations from this normal state can be indicative of struc-
tural aberrations.24 We can therefore use changes in the magni-
tude of these deviations in the subjects’ longitudinal samples to
measure intraindividual changes over time and to estimate the
proportion of cells affected by large-scale aberrations. We
produced the boxplots in Figures 1E, 1K, 4J, S9D, S9G, and S8G
to visualize such changes in BAF variation. In these figures, we
plotted the absolute deviation of BAF values from 0.5 for all
heterozygous SNPs in the region of interest (i.e., ABS (0.5BAF))
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on the y axes. We only included heterozygous SNPs (i.e., those
with a BAF value between 0.2 and 0.8) in these calculations to
increase quality and accuracy of the plots. A larger BAF value devi-
ation from 0.5 corresponds to a larger degree of mosaicism, i.e.,
a higher proportion of cells with a specific aberration. We used t
tests (in cases with two factor levels) or one-way ANOVAs (in cases
with >2 factor levels) to test for significance of such differences.
For themodel illustrated in Figures 1K and S8G, we used the Tukey
Figure 4. Longitudinal Analysis of ULSAM-340, a Single-Born Subject Containing a 13.8 Mb Deletion on 20q, as Detected by LRR and
BAF with the Illumina SNP Array
The size and position of this deletion is typical of MDS patients. This subject, however, has not been diagnosed with MDS. When the
patient was 71 years old, the deletion was only carried by a small proportion of blood cells and was barely detectable, and neither Nexus
CopyNumber software nor R-packageMAD reported this aberration at this age (A, D, and E). R-packageMAD suggested that 50.7% of the
nucleated cells had the deletion when ULSAM-340 was 75 years old (B, F, and G) and that when he was 88 years old, the corresponding
proportion of cells was 36.1% (C, H, and I). qPCR validation experiments showed that the sample taken when the patient was 88 years
old contained 14.5% fewer copies of DNA in the segment as compared to the sample taken when he was 75 years old (Figure 5). The
deviations from 0.5 of the BAF values within the deleted region in the three different sampling stages are illustrated in (J).
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post-hoc test for multiple comparisons to compute differences
between factor-level means after adjusting p values for the
multiple testing.
Quantification of the Number of Cells Affected by
Megabase-Range Aberrations
We calculated the approximate percentage of cells affected by
aberrations in the megabase range by using data from qPCR exper-
iments (the data are described in Figure 5). The qPCR measure-
ments provided the approximate number of DNA molecules that
are affected by an aberration. Assuming that an aberration affects
only one chromosome (i.e., an aberration that is a heterozygous
event) in a diploid genome, we used this number and converted
it to the approximate number of affected cells. Our assumption
is reasonable, given that we are studying normal cells and that
the size of these large-scale aberrations renders them unlikely to
affect both chromosomes (i.e., they are unlikely to be homozygous
[biallelic] events). For example, the relative number of DNA copies
in nucleated blood cells of twin TP25-2 at the age of 77 years
confirmed the array data. To determine these numbers, we used
two primer pairs (41.1 and 42.1) designed within the deleted
region and took five independent measurements for both primer
pairs. These experiments suggested that, at the age of 77, twin
TP25-2 had 30.8% (when primer pair 41.1 was used) and 35.4%
(when primer pair 42.1 was used)—an average of 33.1%—fewer
DNA copies with a 32.5 Mb 5q deletion than did her co-twin at
the same age (Figure 5). If one assumes that this deletion is
affecting one chromosome in a diploid cell, our calculations
suggest that 66.2% of cells contain this deletion.
In order to quantify the level of mosaicism, we also applied an
alternative, published method19,30 based on calculations of the
deviation of BAF values from the expected value of 0.5 for the
heterozygous SNPs in a normal state. This method has been
tailored for data derived from the Illumina SNP platform. The
R-package MAD (Mosaic Alteration Detection) version 0.5–930
identifies the aberrant regions, such as deletions, gains, and
CNNLOHs, and calculates the B deviation (Bdev, deviation from
the expected BAF value of 0.5 for heterozygous SNPs) value, which
is then used for calculation of the number of cells affected by the
aberration. We used the following modified version of the pub-
lished19 formula for deletions, gains, and CNNLOHs:
Proportion of cells with aberration ¼ 2Bdevð0:5þ BdevÞ
Results
Age-Related Accumulation of Megabase-Range
Structural Variants
Our analysis of 159 MZ pairs involved genotyping with
Illumina 600K SNP arrays, confirmation of monozygozity
(>99.9% genotype concordance), CNV calling with Nexus
Copy Number software (BioDiscovery, CA, USA), followed
by inspection of genomic profiles. Validation was per-
formed with a different Illumina array, Nimblegen array,
and qPCR. Comparison of MZ twin pairs, including 19
previously reported pairs,21 identified five large de novo
aberrations of >1 Mb among 81 young or middle-aged
(%55 years) and 78 elderly (R60 years) pairs studied
(Figures 1, 3, 5, and S5). All five large rearrangements
occurred in the older twins, suggesting a relationship
between age and the presence of changes. Tables S1 and
S2 show a description of subjects, cohorts, and statistical
support for the use of Illumina data for the detection of
variants. We expanded on the results from twins by using
two age-stratified groups of single-born subjects. First, we
genotyped DNA from 108 men, all 88 years old, from the
ULSAM (Uppsala Longitudinal Study of Adult Men) cohort
by using the Illumina-1M-Duo array. We found that four
subjects had large-scale rearrangements at the age of
88 years, and the somatic nature of such rearrangements
was established by examination of samples taken from
the same individuals at other time points (Figures 1, 4, 5,
and S8–S10 and Table S1). Second, for the young or
middle-aged single-born control cohort (33–55 years), we
used existing Illumina 550K data from 180 controls from
the ADVANCE (Atherosclerotic Disease, Vascular Function,
and Genetic Epidemiology) study.31,32 Analogous analysis
of ADVANCE subjects did not reveal any cases of large-scale
aberrations. The genotyping quality of 550K experiments
is at least as good as the quality of 1M-Duo arrays, and
the resolution of the 550K array is sufficient for detection
of ~1Mb aberrations that have been uncovered in the
ULSAM cohort (Figures S11 and S12 and Table S6). In
fact, we described a 1.6 Mb deletion by using the 300K
array in twin D8,21 and literature comparing arrays
suggests that the 250K level is sufficient for uncovering
submegabase-range changes.28,33 By studying the twins
and the single-born individuals and by analyzing the two
groups together, we obtained firm statistical support for
age-related accumulation of large structural variants
(with Fisher’s exact test; p value ¼ 0.00052) (Table S2).
Overall, 3.4% of the studied population R60 years old
carries cells containing megabase-range somatic aberra-
tions that are readily detectable by array-based scanning,
whereas none of the younger controls carried aberrations
in this size range. The sensitivity of our analysis to detect
aberrant clones is about 5% of nucleated blood cells.24,25
A previous estimate of 1.7% for somatic mosaicism was
performed in an analysis that was not stratified by age.19
Five subjects harboring large CNVs (twin TP25-2 and
ULSAM-102, -298, -340, and -697) were followed in
repeated samplings collected up to 19 years apart. They
all showed accumulation of aberrant cells with a variation
in the rate of this process. Twin TP25-2 is an example of
slow accumulation of a 5q-deletion clone (Figure 1);
when this twin was 77 years old, two independent
methods (q-PCR and MAD-program-based) suggested
that 66.2% and 50.5% of cells, respectively, contained
a deletion on one copy of chromosome 5. The change in
deviation of BAF within the deleted region when twin
TP25-2 was 70 and 77 years old translates into a 2.2%
increase in cells with the 5q deletion. The latter estimation
was based on analysis with the MAD program. It is note-
worthy that the size and position of this 5q deletion are
typical of myelodysplastic syndrome (MDS).34–38 However,
twin TP25-2 has not been diagnosed with this disease.
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Figure 5. Validation of de novo CNVs by qPCR with SYBR Green
Eleven independent qPCR experiments, each composed of multiple (5–11) independent measurements, are shown. The relative number
of DNA copies in both test loci (white bars) and the control regionUCE3 (gray bars) were plotted. Before we plotted and performed statis-
tical analyses with t tests, we normalized all Ct values by using the control region UCE6. Figure S7 shows the determination of primer
efficiency for each of the primer pairs.
(A and B) Validations for five large-scale (A) and five small-scale (B) aberrations. The dotted line drawn at 100% represents the copy-
number state in control DNA (i.e., that from the normal MZ co-twin, or human female control DNA, or DNA from the same subject
sampled at another age), and error bars indicate standard error of means.
(A) The 5q deletion in twin TP25-2 (Figure 1) was validated with two primer pairs (41.1 and 42.1) designed within the deleted region. In
total, ten independent qPCR experiments showed that ~66.2% of all nucleated blood cells in TP25-2 had the 5q deletion (i.e., an average
of 33.1% [30.8%with primer pair 41.1 and 35.4%with primer pair 42.1] fewer copies of the DNA segment). Similarly, the 20q deletion in
twin TP30-1 (Figure 3) was validated with primer pair 45.1 in five experiments. The 19.8% fewer DNA copies found in the test locus indi-
cates that 39.6% of the nucleated blood cells had the deletion. For ULSAM-340, the array data indicated a longitudinal somatic change in
the number of cells carrying the 20q deletion. Six independent qPCR experiments comparing DNA sampled when ULSAM-340 was 75
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ULSAM-102 is another example of slow accumulation and
contains gains on 1p and 8q (Figure S9). The 1p gain is
stable, whereas the 8q gain shows a statistically significant
(ANOVA: p value <0.05) increase over a period of 10 years.
Consequently, ULSAM-102 probably carries two coexisting
clones with different aberrations. In ULSAM-340 and -697,
the rate of accumulationwas faster and therewas a decrease
in the proportion of cells with aberrations at later sam-
plings. ULSAM-340 contains a 20q deletion, which was
barely detectable at the age of 71 (Figure 4). The number
of cells containing the 20q deletion was estimated by anal-
ysis with the MAD program to be 50.7% when ULSAM-340
was 75 years old and to be 36.1% when he was 88 years
old. ULSAM-340 is another example of an aberration
typical of MDS in a subject without this diagnosis.
However, his clinical history includes thrombocytopenia,
which is normally a part ofMDS clinical features.We there-
fore speculate that this symptom might be due to clonal
expansion of cells with a 20q deletion and suppression of
normal thrombocyte production. Finally, ULSAM-697
was analyzed four times and shows the most pronounced
increase and decrease in the number of cells with
CNNLOH of 4q (Figures 1 and S8). This aberration was
not detectable at the age of 71, reached 58.4% at the age
of 88, and decreased radically to 29.9% of cells at the age
of 90. When ULSAM-697 was 90 years old, we profiled
sorted CD4þ cells, CD19þ cells, granulocytes, and fibro-
blasts, in addition to whole-blood DNA. CD4þ cells, gran-
ulocytes, and whole blood showed similar levels of
aberrant cells, whereas CD19þ cells and fibroblasts ap-
peared normal. We performed all experiments on samples
taken when ULSAM-697 was 90 years old in duplicate with
different types of arrays. Thus, in ULSAM-697, both
lymphoid andmyeloid cells were affected, except for, quite
surprisingly, CD19þ B cells. Overall, the analyses per-
formed on ULSAM-340 and ULSAM-697 suggest that the
cells with aberrations have a higher proliferative potential
than do other cells in the immune system, but they are not
immortalized because they apparently disappear from
circulation.
Small-Scale Structural Aberrations Also Display
Positive Correlation with Age
Given the above results, we tested whether smaller struc-
tural variants would also accumulate with age, and we
used deviations in BAF as the main detection tool because
they can detect mosaicism in as low as 5%–7% of cells24,25
and allow detection of deletions and duplications as well as
CNNLOH. We performed scans for deviations in BAF
values alone and BAF together with LRR in twins by using
a new R-script (Figure S1) that identifies CNV calls for each
MZ pair at various thresholds of DBAF and DLRR. Early
analyses showed that the algorithm was sensitive to the
quality of genotyping because calls were preferentially
observed in co-twins with lower data quality. We therefore
applied strict inclusion criteria by using the NQ score,
which is based on genome-wide noise measurements.
This resulted in the selection of 87 out of 159 MZ pairs
(Table S3). We found that small putative CNVs increased
with age (Figure 2A, linear regression F(1,85) ¼ 54.00,
p < 0.001, Figures S2–S4). We further narrowed the
number of calls by combining the DBAF and DLRR
values >0.35 from both twins in each MZ twin pair, and
this process also indicated that these CNVs accumulate
with age (Figure 2B; F(1,85) ¼ 34.60, p < 0.001). We also
tested whether genotyping quality (DNQ value is the abso-
lute value of the difference in quality score within pairs)
might explain the observed pattern. Importantly, there
was no effect of DNQ on age (F(1,85) ¼ 1.85, p > 0.05), sug-
gesting that the positive correlation with age reflects true
aberrations. Figure 2B displays a total of 827 CNV calls at
378 loci in 87 pairs with an age span of 3–86 years. Plotting
of the 378 calls against the genome shows the nonrandom
distribution and recurrent nature of these CNV calls
(Figure S13). On the basis of frequency and/or location in
the vicinity of known genes, we selected 138 loci for vali-
dation by using a tiling-path array (Nimblegen 135K) in
34 twin pairs. With this platform, 15% of putative CNVs
were validated in the same twin pairs in which they were
first detected by DBAF and DLRR analysis. There was no
bias in the success rate of validation between younger
and older groups (t test: t ¼ 0.7062, p value ¼ 0.4819). In
total, 52 of the 138 loci (38%) included on the 135K array
showed CNVs within 32 of the 34 MZ pairs tested (Figures
2G, 2H, and S6), and the majority of CNVs encompassed
<1 kb. The reason for the discrepancy (i.e., 15% versus
38%) in the validation success rates mentioned above is
probably due, at least in part, to the high stringency of
the DBAF and DLRR analysis that only reported a subset
of preferentially strong calls representing structural vari-
ants and the recurrent nature of loci that are affected by
the small-scale variation. Hence, some true structural vari-
ants were validated in (often multiple) MZ pairs on the
135K array, even though the initial DBAF and DLRR anal-
ysis did not pick them up because the filtering parameters
were too stringent.We selected 5 of these 52 loci for further
validation with qPCR, and all five were confirmed by this
alternative approach (Figure 5). We also performed break-
point-PCR validation in 17 out of the above 52 loci by
using PCR across the deleted region in instances that
and 88 years old showed that the subject had 14.5% fewer copies of the DNA segment when he was 88 years old. In ULSAM-102, the
Illumina array identified a duplication event on both chromosomes 1 and 8 (Figure S9). Given that the proportion of cells with a gained
segment in this subject was relatively stable over time, we used human female genomic DNA as control DNA in these experiments. The
qPCR experiments validated both somatic CNVs.
(B) qPCR validation of five loci with small-scale de novo CNVs withinMZ twins. These loci were identified by Illumina array genotyping
and were confirmed on the Nimblegen 135K array (see also Figures 2G, 2H, and S6). The layout of this panel is similar to that of (A),
described above. For example, the first locus (rs6928830) illustrates de novo CNVs in twin TP31-1 (Figure 2H).
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were presumed to represent the shortest deletions based on
the Illumina and Nimblegen 135K array data. However,
these attempts were not successful. We obtained correctly
sized PCR bands representing wild-type alleles for tested
loci. However, we could not detect any shorter, mutated
alleles that were mapped to the correct genomic regions.
These validation experiments included gel purification of
PCR fragments, PCR-fragment analysis, subcloning in plas-
mids, and Sanger sequencing (details not shown). These
results suggest that the vast majority of the uncovered
small structural variants are due to more complex rear-
rangements involving deletions or gains embedded
together with other structural changes. These results are
in agreement with a recent sequencing-based validation
analysis of CNV loci; the analysis showed that as few as
5% of CNVs suspected to represent gains or deletions are
in fact ‘‘pure blunt-end breakpoints.’’39 Details for the 52
validated loci are shown in Table S4, which includes infor-
mation about genes affected by the variation. The results
presented in Table S4 and Figure S13 emphasize the
recurrent nature of the 52 validated loci. For example,
out of the 52 loci, 13 only occurred once in any of the 34
tested twin pairs, whereas the remaining 39 were recurrent
and occurred 2–16 times in the same set of MZ twin
pairs. The number of CNVs per pair validated with the
135K Nimblegen array ranged from 1 to 32 (median 6)
(Table S7). In summary, the deviation between MZ co-
twins ranged from 0 to 51,040 bp (median 4,995 bp),
and the latter corresponds to ~0.0000016% genome-wide
divergence.
By using the small-scale CNV pipeline, we analyzed 18
pairs of MZ twins that were sampled twice, 10 years apart
(Figures 2E, 2F, and S1 and Table S8). Analyses were per-
formed in two ways: as an interindividual comparison of
one twin to its co-twin at the first and second sampling
and as an intraindividual comparison of the two samplings
of a single twin. Both types of comparisons suggest varia-
tion in the dynamics of changes between co-twins and
show both increases and decreases over a period of 10 years
in the number of calls in different twin pairs. Interestingly,
this evidence for the dynamics of small-scale CNVs over
time (Figure 2E) is consistent with the results from longitu-
dinal analyses of large-scale aberrations in ULSAM-697 and
ULSAM-340 (Figures 1 and 4), suggesting both increases
and decreases over time in the number of cells containing
different variants.
Discussion
The phenotypic consequences of accumulating aberra-
tions are an interesting aspect of our results. In two
subjects diagnosed with chronic lymphocytic leukemia
(CLL), we detected multiple changes consistent with the
disease (Figure S10). These findings are not unexpected:
Our population-based cohort was not preselected against
any diagnoses, and CLL is the most prevalent leukemia
among the elderly.40 However, it is surprising that appar-
ently healthy subjects have aberrations characteristic of
MDS. A typical 5q deletion (observed in one subject) and
a 20q deletion (observed in two subjects) are among the
most common aberrations in patients diagnosed with
MDS.34–38 Trisomy 8 is also a recurrent aberration in
MDS, and ULSAM-102 displays a restricted 8q gain; it
remains unclear whether this gain is related to MDS.
None of the above-mentioned individuals were diagnosed
with MDS, and their cases might represent an indolent,
subclinical form of MDS. In two individuals followed in
longitudinal sampling (i.e., ULSAM-340 and -697), we
observed not only an increase but also a clear subsequent
decrease in the proportion of nucleated blood cells with
aberrations (Figures 1, 4, and S8). These results suggest an
‘‘autocorrection’’ of the immune system, given that the
aberrant clones are apparently disappearing from circula-
tion. Similar expansions of preleukemic clones containing
gene fusions specific to acute leukemia have been
described in newborns;41 the gene fusions TEL-AML1 and
AML1-ETO were present in cord blood at a frequency
1003 greater than the frequency that is associated with
the risk of developing the corresponding leukemia.
The presented data are probably only part of all the
somatic changes that actually occurred in the studied
cohorts because balanced inversions and translocations
escape our detection and because we interrogated a fraction
of all the nucleotides in the genome. Furthermore, we only
detected high-frequency aberrations, presumably because
these aberrations provided the affected cells with a prolifer-
ative advantage, which lead to clonal expansion above
the detection limit of ~5% of cells. It follows from this
reasoning that deleterious aberrations leading to prolifera-
tive disadvantage or aberrations that are neutral from the
point of view of the proliferative potential go undetected.
Nevertheless, the chromosomal regions (e.g., those that
contain the 20q deletion) and loci affected in a recurrent
fashion (Figure S13 and Table S4) are candidates for con-
taining common and redundant age-related defects in
human blood cells. These mutations are presumed to
provide the affected cells with a mild proliferative advan-
tage without transforming the affected cells into immortal-
ized cancer clones. However, the proliferative advantage
for a limited number of cells will most likely affect the
overall complexity of cell clones present in blood and
should therefore be discussed in the context of immunose-
nescence, which, in fact, involves loss of complexity of cell
clones in both B and T cell lineages.42,43 Our results might
therefore help to explain the cause of age-related reduction
in the number of cell clones in the blood. This reduction
could lead to a less diverse immune system caused by the
accumulation of genetic changes that induce the expan-
sion of a limited number of clones. We also anticipate
that extension of our work will allow determination of
the genetic age of different somatic cell lineages and esti-
mation of possible individual differences between genetic
and chronological age.
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